Agios Pharmaceuticals, Inc. (AGIO)

Name: Agios Pharmaceuticals, Inc. (AGIO) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name AGIOS PHARMACEUTICALS, INC. · CIK 0001439222 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Agios Pharmaceuticals, Inc. reported revenue of $54.03M. Revenue grew 48.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $98.34M.

Key ratios (year ended 2025-12-31)

88.3%

Gross margin (computed)

-873.9%

Operating margin

-764.0%

Net margin

-34.6%

Return on year-end equity

48.0%

Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-08-06

Headquarters locality: Cambridge · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$98.34M	$54.03M	$36.50M	$26.82M	$14.24M	$0	$0	$117.91M	$94.39M	$43.01M	$69.89M
Cost of Revenue	$7.87M	$6.34M	$4.17M	$2.88M	$1.70M	$0	$0	$1.32M	$1.40M	$0	$0
Gross Profit (computed)	$90.47M	$47.68M	$32.33M	$23.94M	$12.54M	n/a	n/a	n/a	n/a	n/a	n/a
R&D Expense	$356.75M	$339.54M	$301.29M	$295.53M	$279.91M	$256.97M	$220.81M	$214.26M	$341.32M	$292.68M	$220.16M
Operating Income	-$459.02M	-$472.13M	-$425.74M	-$391.49M	-$389.05M	-$378.42M	-$335.92M	-$316.27M	-$362.48M	-$320.79M	-$200.99M
Depreciation & Amortization	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$8.09M	$7.17M	$6.43M	n/a
EBITDA	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-$308.18M	-$355.31M	-$314.36M	n/a
Net Income	-$411.29M	-$412.78M	$673.73M	-$352.09M	-$231.80M	$1.60B	-$327.37M	-$411.47M	-$346.03M	-$314.67M	-$198.47M
EPS (Diluted)	n/a	-$7.12	$11.64	-$6.33	-$4.23	$26.55	-$4.74	-$6.86	n/a	n/a	n/a
Total Assets	$1.11B	$1.30B	$1.66B	$937.12M	$1.24B	$1.44B	$852.95M	$890.74M	$858.46M	$614.40M	$619.09M
Total Liabilities	$82.40M	$104.11M	$122.24M	$126.10M	$137.90M	$145.76M	$453.45M	$250.21M	$170.92M	$238.89M	$260.50M
Shareholders' Equity	$1.03B	$1.19B	$1.54B	$811.02M	$1.10B	$1.29B	$399.50M	$640.53M	$687.54M	$375.50M	$358.59M
Cash & Equivalents	$99.65M	$89.13M	$76.25M	$88.20M	$139.26M	$203.13M	$127.44M	$80.93M	$70.50M	$102.72M	$160.75M
Operating Cash Flow	-$360.60M	-$372.98M	-$389.84M	-$296.06M	-$309.48M	-$407.32M	-$290.76M	-$370.62M	-$304.42M	-$285.23M	$38.56M
Capital Expenditures	$4.66M	$4.32M	$1.69M	$999.0K	$4.88M	$5.74M	$14.11M	$12.03M	$6.99M	$4.63M	$9.91M
Free Cash Flow	-$365.25M	-$377.29M	-$391.53M	-$297.06M	-$314.36M	-$413.06M	-$304.87M	-$382.65M	-$311.41M	-$289.86M	$28.65M
Shares Outstanding	59.60M	58.45M	57.16M	55.95M	55.04M	54.33M	69.29M	68.40M	58.22M	48.83M	42.22M
Weighted Average Diluted Shares	n/a	57.97M	57.89M	55.65M	54.79M	60.45M	69.00M	59.99M	n/a	n/a	n/a
EPS (Basic)	n/a	-$7.12	$11.86	-$6.33	-$4.23	$26.55	-$4.74	-$6.86	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView